Clinical Trials · NCT03331289
Can Exenatide Prevent Increase in EGP in Response to Dapagliflozin-induced Increase in Glucosuria
- Phase
- Phase 4
- Recruitment status
- Completed
- Sponsor
- The University of Texas Health Science Center at San Antonio
- Enrollment
- 107
- Start date
- Feb 2018
- Locations
- 1 site, United States
- Primary endpoint
- Change in EGP From Baseline to Post-oral Glucose Load.